Supplementary file 1_Three-year real-world effectiveness, treatment persistence, and plann

Supplementary file 1 contains data from a single-center retrospective cohort study of 50 patients in Japan initiating anti-CGRP monoclonal antibody therapy for migraine prevention between May 2021 and June 2022. The dataset includes longitudinal outcomes such as monthly migraine days (MMDs), Migraine Disability Assessment Scale (MIDAS), Headache Impact Test (HIT-6), and Visual Analogue Scale (VAS) scores assessed at baseline and over 36 months. The study, authored by Hideyo Kasai and licensed CC-BY-4.0, analyzes treatment persistence, responder rates, and reasons for discontinuation.

Use Cases

• Analyze long-term treatment persistence rates based on the 36-month follow-up data
• Evaluate the durability of responder rates (≥50%, ≥75%, 100%) over the three-year period
• Compare clinical outcomes between episodic migraine and high-frequency/chronic migraine subgroups
• Investigate reasons for treatment discontinuation, including planned discontinuation after goal attainment

Strengths

• Provides 36-month longitudinal data, which the description notes is scarce for this class of drugs
• Includes multiple standardized clinical outcome measures: MMDs, MIDAS, HIT-6, and VAS
• Reports specific patient counts and outcomes, such as 56% of patients continuing therapy for 3 years

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• Data is from a single center with 50 patients, limiting generalizability

Provenance

Source

Hideyo Kasai

Collection Method

Single-center retrospective cohort study

Time Range

Patient initiation between May 2021 and June 2022, with outcomes tracked for 36 months

Freshness

Last updated 2026-05-13 04:41:24; freshness should be verified

Geography

Japan